Complete Genomics

Complete Genomics to Present its Multiple, Innovative Sequencing Platforms at BIOTECH SHOWCASE™ 2023

Retrieved on: 
Giovedì, Dicembre 29, 2022
Organization, JPMorgan Chase, JP, SAN, Drug discovery, Biotechnology, Partnership, Completeness, Complete Genomics, Doctor of Philosophy, MPS, Genomics, Fine chemical, Pharmaceutical industry

SAN JOSE, Calif., Dec. 29, 2022 /PRNewswire/ -- Complete Genomics Inc（https://completegenomics.mgiamericas.com/）, a subsidiary of MGI Tech Co., Ltd., today announced that it is presenting at Biotech Showcase™ 2023, taking place in San Francisco at the same time as the JP Morgan healthcare conference. Registered attendees can view Complete Genomics presentation live and through 24x7 on-demand access if scheduling does not allow viewing during the main event week.

Key Points: 
  • Complete Genomics offers complete high throughput sequencing instrumentation and related products, including sample extraction, library prep, automation system, sequencing platforms, and bioinformatics.
  • Rade Drmanac, PhD, Chief Scientific Officer, will provide an overview of the complete suite of high throughput sequencing instruments and related products.
  • Complete Genomics sequencing platforms are based on DNBSEQTM, sample extraction, library prep, automation system, and bioinformatics to the US market and beyond.
  • Moreover, Complete Genomics will launch at Biotech Showcase the "Empowerment Program America", which will bring choice to sequencing by collaborating with researchers to develop grant proposals.

Callon Petroleum Company Announces New Officer Appointments

Retrieved on: 
Martedì, Novembre 29, 2022
Permian, Complete Genomics, Pioneer Natural Resources, Information technology, Engineering, University, University of Colorado Denver Business School, Paloma, Pioneer, El Paso Corp., Colorado School of Mines, Parsley, Moses Austin, NYSE, University of Houston–Downtown College of Sciences and Technology, Business administration, Information system, EP, CPE, Acquisition, Management, Petroleum, Science

HOUSTON, Nov. 29, 2022 /PRNewswire/ -- Callon Petroleum Company (NYSE: CPE) ("Callon" or the "Company") today announced that the Company has added to its management team with three hires across areas of strategic focus for the Company.

Key Points: 
  • HOUSTON, Nov. 29, 2022 /PRNewswire/ -- Callon Petroleum Company (NYSE: CPE) ("Callon" or the "Company") today announced that the Company has added to its management team with three hires across areas of strategic focus for the Company.
  • In recent months, Callon has welcomed Carrie Endorf as Vice President of Asset Development & Technology, Doug Genrich as Vice President of Drilling & Completions, and Angie Day as Chief Information Officer and Vice President of Information Technology.
  • Prior to Callon, Doug served as Chief Operating Officer for Paloma Resources, where he managed the company's Mid-Continent operations in Oklahoma's Stack/Merge play.
  • Callon Petroleum Company is an independent oil and natural gas company focused on the acquisition, exploration and development of high-quality assets in the leading oil plays of South and West Texas.

Reneo Pharmaceuticals Reports Third Quarter 2022 Financial Results

Retrieved on: 
Martedì, Novembre 8, 2022
Myopathy, Gene, Death, Severe cognitive impairment, Brain, Company, Program, Mitochondrion, A-DNA, Conference, Security (finance), Complete Genomics, Enzyme, Muscle, INFORM, Hypoglycemia, Lethargy, U.S. Securities and Exchange Commission, Research, Lotte New York Palace Hotel, Sudden death, Patient, CEO, Metabolism, Private Securities Litigation Reform Act, Total permanent disability insurance, Protein, STRIDE, Nasdaq, Tissue, Liver, ATP, Mitochondrial disease, Exercise intolerance, PMM, Myalgia, Disorder, Adenosine triphosphate, Life, Deafness, Trial of the century, GLOBE, Investment, Guidelines International Network, Rhabdomyolysis, Encephalopathy, DNA, Home After Three Months Away, Muscle weakness, Heart, Prognosis, Pharmaceutical industry, Birth control, Nightclub, Dietary supplement

IRVINE, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended September30, 2022.

Key Points: 
  • IRVINE, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quarter ended September30, 2022.
  • We continued to advance our REN001 development programs during the third quarter, said Gregory J. Flesher, President and CEO of Reneo Pharmaceuticals.
  • We remain on track to announce topline data from this study in the fourth quarter of 2023.
  • Furthermore, we announced positive results from the Phase 1b study in long-chain fatty acid oxidation disorders (LC-FAOD) patients with nuclear DNA (nDNA) defects.

Complete Genomics, part of MGI, Announces Next-Generation Sequencing Platforms at ASHG Annual Meeting

Retrieved on: 
Mercoledì, Ottobre 26, 2022
Time, Complete Genomics, Science, Workflow, Organization, Completeness, Society, Technology, MGI, NGS, American Society of Human Genetics, Human genetics, Genomics, FASTQ, ASHG, Fine chemical, Computer data storage

MGI isa global life science tool provider offeringlab automation and NGS sequencing platforms around the world.

Key Points: 
  • MGI isa global life science tool provider offeringlab automation and NGS sequencing platforms around the world.
  • Complete Genomicsoffers complete NGS instrumentation and related products, including sample extraction, library prep, automation system, sequencing platforms, and bioinformatics.
  • This technology is available on all sequencing platforms,which eliminates index hopping and clonal errors during the sequencing step of NGS workflow.
  • At ASHG, Complete Genomics showcases DNBSEQ-E25*, DNBSEQ-G400*, DNBSEQ-T7*, and DNBSEQ-T10x4* at the MGI booth (#1803).

VIP Completions Unveils Ultimate Private Jet Refurbishment in Customized Boeing 767 VIP

Retrieved on: 
Lunedì, Maggio 2, 2022
TIME, Artificial leather, Table, Complete Genomics, Negotiation, Carbon, Maintenance, Boeing, G550, Sikorsky, LED, Cessna Citation X, Founder, Founder CEO, Gulfstream G550, IPad, DJ, Wool, NIL, Gulf Stream, VIP, Aviation, Mark (given name), Aircraft, 767, Dream, Conference, CEO, Coffee, Redrock Broadcasting, Altitude, Airline, Interior design, Restaurant

FT. LAUDERDALE, Fla., May 2, 2022 /PRNewswire/ -- VIP Completions, providers of bespoke aircraft completions, design, and refurbishment services, is proud to announce the company's most recent project: The comprehensive interior and exterior renovation of a Boeing 767 VIP. The impressive private jet, which seats 33 and sleeps 17, features premium luxury brands and state-of-the-art technology. 

Key Points: 
  • The impressive private jet, which seats 33 and sleeps 17, features premium luxury brands and state-of-the-art technology.
  • VIP Completions' clientele, such as the owner of the customized Boeing 767 VIP, entrust the Ft. Lauderdale-based company to handle their aircraft refurbishment projects from A to Z.
  • Based in FT. Lauderdale, FL, The VIP Completions team brings more than 20 years of experience to business aircraft Completions and refurbishment.
  • Having completed aircraft ranging from light business jets to corporate airliners, the VIP Completions team is primarily focused on long-range business aircraft.

Cold Bore Technology Recognized By Darcy Partners Among Top 10 Innovators in Drilling & Completions in 2021

Retrieved on: 
Mercoledì, Gennaio 26, 2022
Mining, Minerals, Environment, Utilities, Oil, Gas, Energy, Natural Resources, Data collection, Automation, Workforce, Complete Genomics, Growth, Communication, Sourcefire Vulnerability Research Team, Daou Technology Inc., LinkedIn, Technology, Face, CEO, Cryptocurrency

Cold Bore Technology Inc. (Cold Bore), the leader in frac completions automation and platform technology, announced today that it has been recognized by notable innovation advisory firm, Darcy Partners, as one of the Top 10 Technologies from 2021 in Drilling and Completions.

Key Points: 
  • Cold Bore Technology Inc. (Cold Bore), the leader in frac completions automation and platform technology, announced today that it has been recognized by notable innovation advisory firm, Darcy Partners, as one of the Top 10 Technologies from 2021 in Drilling and Completions.
  • Combined with analysis from its Research Team about technology developments and market traction, it selects the Top 10 Innovators from 2021 in each of its coverage channels.
  • In a statement released on LinkedIn , Darcy Partners remarked that 2021 was characterized by a recovery in activity in both Drilling and Completions from the lows of 2020, a trend we expect to see continue into 2022.
  • Cold Bore Technology Inc. (Cold Bore) is a global leader in completion optimization technology, developing the first Completions Operating System through Cold Bores SmartPAD service.

Forum Energy Technologies Announces CEO Succession

Retrieved on: 
Lunedì, Dicembre 6, 2021
Energy, Other Manufacturing, Manufacturing, Oil, Gas, FET, Senior, Forum Energy Technologies, Safety, Complete Genomics, Purdue University, Industrial engineering, Company, NYSE, Leadership, Solution, Board of directors, Board, Efficiency, Growth, Natural gas, Management

Forum Energy Technologies, Inc. (NYSE: FET) today announced that as part of the companys executive management succession planning process, its Board of Directors appointed Mr. Neal Lux as President and Chief Executive Officer, effective February 18, 2022.

Key Points: 
  • Forum Energy Technologies, Inc. (NYSE: FET) today announced that as part of the companys executive management succession planning process, its Board of Directors appointed Mr. Neal Lux as President and Chief Executive Officer, effective February 18, 2022.
  • Together we will focus on developing our traditional energy equipment and grow our non-oil and gas portfolio, especially new energy products.
  • FET (Forum Energy Technologies) is a global company, serving the oil, natural gas, industrial and renewable energy industries.
  • FET provides value added solutions that increase the safety and efficiency of energy exploration and production.

Resolve Biosciences Strengthens Leadership Team with Appointment of Frank Zhong as Chief Technology Officer

Retrieved on: 
Martedì, Novembre 2, 2021
Software, Research, Hardware, Pharmaceutical, Data Management, Oncology, Technology, Infectious Diseases, Genetics, Science, Nanotechnology, Biotechnology, Health, Science, Research, Biotechnology, BGI, University, Technology, Genomics, Physics, BGI Group, Cartography, Biomedical Research, Illumina, Inc., View, Ministry of Education (Malaysia), Monheim am Rhein, Infection, Euronext, Resolve, Learning, List of life sciences, Neuroscience, CEO, Pacific Biosciences, DNA, Silicon, Doctor of Philosophy, Complete Genomics, Associate, CTO, Peking University, Management, Microscope

Resolve Biosciences , the pioneer in Molecular Cartography, today announced the appointment of Frank Zhong, PhD, as Chief Technology Officer.

Key Points: 
  • Resolve Biosciences , the pioneer in Molecular Cartography, today announced the appointment of Frank Zhong, PhD, as Chief Technology Officer.
  • The company also recently announced the appointment of Chris Barbazette as Chief Commercial Officer and Erik Wiberg as Chief Financial Officer.
  • The technology has been under development since 2016 and is currently available through Resolve Biosciences commercial service laboratory.
  • Resolve Biosciences, the Resolve Biosciences logo, and Molecular Cartography are trademarks of Resolve Biosciences.

Illumio Appoints Kathleen Swift as Chief People Officer

Retrieved on: 
Martedì, Ottobre 19, 2021
Zero, People, Acquisition, Policy, Ruckus Networks, Equity, Complete Genomics, Extreme Networks, Risk, Organization, CPO, Growth, Genomics, Silver, Silver Peak, Swift, Diversity, SVP, CEO, Business administration, IPO, SD, GLOBE, Learning, California, BOLD, Culture, Inclusion, Management, Risk management

SUNNYVALE, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Illumio, Inc. , the pioneer and leader of Zero Trust Segmentation,today announced the appointment of Kathleen Swift as Chief People Officer (CPO).

Key Points: 
  • SUNNYVALE, Calif., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Illumio, Inc. , the pioneer and leader of Zero Trust Segmentation,today announced the appointment of Kathleen Swift as Chief People Officer (CPO).
  • Swift has over 20 years of experience leading and scaling global human resources (HR) organizations and joins Illumio from BOLD, a technology company for job seekers, where she served as Chief Human Resources Officer.
  • Its incredibly exciting to join the Illumio team during a period of exponential growth, said Swift.
  • Prior to Illumio, Kathleen served as chief human resources officer at BOLD.

Dr. Cheng-Chi Chao joins ChemPartner as Vice President and Head of Immunotherapy and Inflammation

Retrieved on: 
Martedì, Marzo 23, 2021
Branches of biology, Clinical medicine, Medicine, Cancer immunotherapy, Immunotherapy, Virotherapy, Cancer vaccine, BGI, Complete Genomics, Applied genetics, Biotechnology

SHANGHAI, March 23, 2021 /PRNewswire/ --Shanghai ChemPartner announced today the appointment of Cheng-Chi Chao, Ph.D. as Vice President and Head of Immunotherapy and Inflammation.

Key Points: 
  • SHANGHAI, March 23, 2021 /PRNewswire/ --Shanghai ChemPartner announced today the appointment of Cheng-Chi Chao, Ph.D. as Vice President and Head of Immunotherapy and Inflammation.
  • Prior to joining ChemPartner, Dr. Chao was the CTO/head of R&D at GenoImmune (a BGI company) in China and held a senior director position of cancer immunotherapy at Complete Genomics (a BGI company) in the U.S.
  • He oversaw discovery research and development for neoantigen-based immunotherapy and was responsible for establishing emerging platform technologies for cell therapy and cancer vaccines.
  • Shanghai ChemPartner serves a diverse global client base and has laboratories, business offices, and representatives in the US, Europe, China, and Japan.